С Википедије, слободне енциклопедије
Frovatriptan Prodajno ime Frova, Frovelan, Miguard Drugs.com Monografija Način primene Oralno Poluvreme eliminacije 26 h Izlučivanje Renalno
CAS broj 158747-02-5 Y ATC kod N02CC07 (WHO PubChem CID 77992 DrugBank DB00998 Y ChemSpider 70378 Y ChEMBL CHEMBL1279 Y Formula C 14 H 17 N 3 O Molarna masa 243,304
CN[C@@H]1CCC2=C(C1)C1=C(N2)C=CC(=C1)C(N)=O
InChI=1S/C14H17N3O/c1-16-9-3-5-13-11(7-9)10-6-8(14(15)18)2-4-12(10)17-13/h2,4,6,9,16-17H,3,5,7H2,1H3,(H2,15,18)/t9-/m1/s1
Y Key:XPSQPHWEGNHMSK-SECBINFHSA-N
Y
Frovatriptan je organsko jedinjenje , koje sadrži 14 atoma ugljenika i ima molekulsku masu od 243,304 Da .[1] [2] [3] [4] [5] [6] [7] [8]
^ Markus F, Mikko K: Frovatriptan review. Expert Opin Pharmacother. 2007 Dec;8(17):3029-33. PMID 18001261
^ Easthope SE, Goa KL: Frovatriptan. CNS Drugs. 2001;15(12):969-76; discussion 977-8. PMID 11735616
^ Balbisi EA: Frovatriptan: a review of pharmacology, pharmacokinetics and clinical potential in the treatment of menstrual migraine. Ther Clin Risk Manag. 2006 Sep;2(3):303-8. PMID 18360605
^ Balbisi EA: Frovatriptan succinate, a 5-HT1B/1D receptor agonist for migraine. Int J Clin Pract. 2004 Jul;58(7):695-705. PMID 15311727
^ Elkind AH, Wade A, Ishkanian G: Pharmacokinetics of frovatriptan in adolescent migraineurs. J Clin Pharmacol. 2004 Oct;44(10):1158-65. PMID 15342617
^ Jhee SS, Shiovitz T, Crawford AW, Cutler NR: Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review. Clin Pharmacokinet. 2001;40(3):189-205. PMID 11327198
^ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs” . Nucleic Acids Res . 39 (Database issue): D1035—41. PMC 3013709 PMID 21059682 . doi :10.1093/nar/gkq1126 . уреди ^ David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets” . Nucleic acids research . 36 (Database issue): D901—6. PMC 2238889 PMID 18048412 . doi :10.1093/nar/gkm958 . уреди ^ Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods” . J. Phys. Chem. A . 102 : 3762—3772. doi :10.1021/jp980230o . ^ Tetko IV, Tanchuk VY, Kasheva TN, Villa AE (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices” . Chem Inf. Comput. Sci . 41 : 1488—1493. PMID 11749573 . doi :10.1021/ci000392t . уреди ^ Ertl P.; Rohde B.; Selzer P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties” . J. Med. Chem . 43 : 3714—3717. PMID 11020286 . doi :10.1021/jm000942e . уреди
Molimo Vas, obratite pažnju na važno upozorenje oblasti medicine (zdravlja) .
. PMID 21059682. doi:10.1093/nar/gkq1126.
